

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run On: May 29, 2003, 09:30:10 ; Search time 69 seconds
(without alignments)
44.417 Million cell updates/sec

Title: US-10-050-688-6

Perfect score: 131

Sequence: 1 AGYFDEKRGDACEGDSGGPFV 23

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Minimum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

A_Geneseq_101002.*

- 1: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1980.DAT.*
- 2: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1981.DAT.*
- 3: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1982.DAT.*
- 4: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1983.DAT.*
- 5: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1984.DAT.*
- 6: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1985.DAT.*
- 7: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1986.DAT.*
- 8: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1987.DAT.*
- 9: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1988.DAT.*
- 10: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1989.DAT.*
- 11: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1990.DAT.*
- 12: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1991.DAT.*
- 13: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1992.DAT.*
- 14: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1993.DAT.*
- 15: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1994.DAT.*
- 16: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1995.DAT.*
- 17: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1996.DAT.*
- 18: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1997.DAT.*
- 19: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1998.DAT.*
- 20: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA1999.DAT.*
- 21: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA2000.DAT.*
- 22: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA2001.DAT.*
- 23: /SIDS2/gcgdata/geneseq/genesexp-emb1/AA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	131	100.0	23	20	AAW83414
2	131	100.0	23	21	AAW83414
3	131	100.0	23	22	AAW70363
4	131	100.0	23	23	AAE22563
5	131	100.0	23	23	AAE220159
6	131	100.0	23	23	AAW50858
7	131	100.0	116	20	AAW59115
8	131	100.0	259	18	AAW11545
9	131	100.0	295	16	AAW74775
10	131	100.0	295	16	AAW74776

11	131	100.0	295	16	AAW74777	Mutant thrombin E2
12	131	100.0	295	16	AAW74778	Mutant thrombin E2
13	131	100.0	295	16	AAW74779	Mutant thrombin E2
14	131	100.0	295	16	AAW74780	Mutant thrombin E2
15	131	100.0	295	16	AAW76033	Mutant thrombin E2
16	131	100.0	295	16	AAW76034	Mutant thrombin R2
17	131	100.0	295	16	AAW76035	Mutant thrombin R2
18	131	100.0	295	16	AAW76036	Mutant thrombin R2
19	131	100.0	295	16	AAW76037	Mutant thrombin W5
20	131	100.0	295	16	AAW76038	Mutant thrombin W5
21	131	100.0	295	16	AAW76039	Mutant thrombin W5
22	131	100.0	295	16	AAW76040	Mutant thrombin W5
23	131	100.0	295	18	AAW22892	Human mature throm
24	131	100.0	295	21	AAW08633	Amino acid sequenc
25	131	100.0	308	20	AAW99109	Human prothrombin
26	131	100.0	376	14	AAW41797	Human CD4-thrombin
27	131	100.0	376	23	AAW42789	Human CD4-thrombin
28	131	100.0	376	23	AAW42789	Human CD4-thrombin
29	131	100.0	579	14	AAW35763	Prothrombin (PT)
30	131	100.0	579	18	AAW11546	Human prothrombin
31	131	100.0	579	18	AAW11544	Human prothrombin
32	131	100.0	579	20	AAW99108	Human prothrombin
33	131	100.0	615	14	AAW38741	Human prothrombin
34	131	100.0	615	17	AAW96215	Human prothrombin
35	131	100.0	615	17	AAW90377	Human prothrombin
36	131	100.0	622	18	AAW11543	Human prothrombin
37	131	100.0	622	20	AAW49566	Platelet membrane
38	124	94.7	111	20	AAW99113	Bovine zeta 2 pret
39	124	94.7	308	20	AAW99107	Bovine prothrombin
40	124	94.7	582	20	AAW99106	Bovine prothrombin
41	123	93.9	23	23	AAW78376	Thrombin peptide d
42	90	68.7	259	16	AAW76041	Mutant thrombin se
43	81	61.8	14	18	AAW10751	Thrombin B chain a
44	81	61.8	15	18	AAW10750	Thrombin B chain a
45	81	61.8	15	22	AAW83282	Modified RGD pepti

ALIGNMENTS

RESULT 1

AAW83414

ID: AAW83414 standard; peptide; 23 aa.

XX

AC AAW83414;

XX 26-FEB-1999 (first entry)

XX Cell growth/adhesion promoting peptide #1.

XX Cell growth; adhesion; promotion; medical treatment; injury;

XX Biotissue; bone reinforcement; nerve regeneration; RMP resin.

XX Synthetic.

XX JP10316581-A.

XX 02-DEC-1998.

XX 15-MAY-1997; 97JP-0140885.

XX 15-MAY-1997; 97JP-0140885.

XX (KURS) KURARAY CO LTD.

XX WPI; 1999-076400/07.

XX Material for medical treatment comprises new peptide - used for

XX covering injuries, promoting adhesion of bio-tissues, bone

XX reinforcing and nerve regeneration

XX Claim 1; Page 12; 14pp; Japanese.

AU3

CC The present invention describes a material for medical treatment which
 CC comprises one or more peptides of the formula XAEGULMPROQY, or their
 CC salts, immobilised on a substrate: where X = H, CH3CO or CH3COLys;
 CC A = Ser or Thr; D = Ile, Val or Leu; E = Lys or Arg; G = Ile, Val or
 CC Leu; J = Gly or Ala; L = Ile, Val or Leu; M = Gly or Ala; Q = Gly, Ala
 CC or Gly-Lys-Lys-Gly; Y = OH or NH2. Also described is an agent for cell
 CC growth promotion and/or cell adhesion promotion containing the above
 CC peptide or its salt as the active component. The peptide and its salt
 CC can be used for covering injuries, promoting adhesion of tissues,
 CC bone reinforcing and nerve regeneration. The present sequence represents
 CC a specifically claimed peptide of the present invention.
 XX Sequence 23 AA;

Query Match 100.0%; Score 131; DB 20; Length 23;
 Best Local Similarity 100.0%; Pred. No. 3.1e-08;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGYKPDGKRGDACEGDSGGPFV 23
 DB 1 AGYKPDGKRGDACEGDSGGPFV 23

RESULT 2
 912893
 AAB12893 standard; peptide; 23 AA.

AC AAB12893;
 DT 02-NOV-2000 (first entry)
 DE Nerve tissue regenerative peptide SEQ ID #8.
 KW Nerve regeneration; nerve cell proliferation; axon extension; treatment;
 KW central nervous system disorder; peripheral nervous system disorder;
 KW spinal disorder, head injury; cerebrovascular disorder.
 OS Synthetic.
 XX JP2000143531-A.
 PN 23-MAY-2000.
 XX 11-AUG-1999; 99JP-0227108.
 XX 09-SEP-1998; 98JP-0270498.
 XX (KURS) KURARAY CO LTD.
 XX (NISHA) NISHIMURA Y.
 XX (SUZU) SUZUKI Y.
 XX (TANI) TANIHARA M.
 XX WPI; 2000-415772/36.

New nerve regeneration material -
 Claim 2; Page 5; 17pp; Japanese.
 This invention relates to a new nerve regenerative material which
 contains a peptide immobilised to a base which consists of a
 polysaccharide gel such as alginate acid. Sequences AAB12886-B12899
 represent examples of the peptides used in the nerve regeneration
 material. The peptide containing material causes nerve cell
 proliferation and also causes axonal extension. The material can be used
 for the treatment of central or peripheral nervous system disorders,
 spinal disorders, head injury or cerebrovascular disorders.

Query Match 100.0%; Score 131; DB 21; Length 23;
 Best Local Similarity 100.0%; Pred. No. 3.1e-08;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGYKPDGKRGDACEGDSGGPFV 23
 DB 1 AGYKPDGKRGDACEGDSGGPFV 23

RESULT 4
 AAE22563
 ID AAE22563 standard; peptide; 23 AA.
 XX AAE22563;
 XX 26-JUL-2002 (first entry)
 DE Human thrombin high affinity receptor binding domain.
 DE Human; proteolytically activated receptor for thrombin; neutrophil;
 KW

QY 1 AGYKPDGKRGDACEGDSGGPFV 23
 DB 1 AGYKPDGKRGDACEGDSGGPFV 23

RESULT 3
 AAB70363
 ID AAB70363 standard; peptide; 23 AA.
 XX AAB70363;
 XX 02-MAY-2001 (first entry)
 DE Human thrombin receptor binding domain peptide SEQ ID NO:8.
 DE Neutrophil cell chemotactic; wound healing; inflammation; vulnerary;
 DE anti-inflammatory.
 KW Homo sapiens.
 OS US6184342-B1.
 PN 06-FEB-2001.
 XX 28-OCT-1994; 94US-0330594.
 XX 28-OCT-1994; 94US-0330594.
 XX (CHRY-) CHRYSALIS BIOTECHNOLOGY INC.
 XX Carney DH, Ramakrishnan S;
 XX WPI; 2001-202003/20.

New synthetic neutrophil cell chemotactic peptides, useful for
 generating antibodies for modulating neutrophil chemotaxis in immune
 response and wound healing
 Example 2; Column 6; 15pp; English.
 The present invention describes a synthetic peptide (I) which is a
 neutrophil cell chemotactic agent. (I) has vulnerary and
 anti-inflammatory activities. (I) is useful as a potent neutrophil cell
 chemotactic agent and for generating antibodies against the peptides,
 which are useful for modulating neutrophil recruitment to a wound site
 for enhancing or inhibiting inflammation and early effects of wound
 healing. Neutrophil response to (I) is specific, since monocytes and
 fibroblasts do not show any expression of the receptor to which (I)
 binds. The present sequence represents a human thrombin receptor binding
 domain peptide which is used in an example from the present invention.

Query Match 100.0%; Score 131; DB 22; Length 23;
 Best Local Similarity 100.0%; Pred. No. 3.1e-08;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGYKPDGKRGDACEGDSGGPFV 23
 DB 1 AGYKPDGKRGDACEGDSGGPFV 23

RESULT 4
 AAE22563
 ID AAE22563 standard; peptide; 23 AA.
 XX AAE22563;
 XX 26-JUL-2002 (first entry)
 DE Human thrombin high affinity receptor binding domain.
 DE Human; proteolytically activated receptor for thrombin; neutrophil;
 KW